Genomics-Guided Radiotherapy in Cancer

Guest Editors:

Dr. Sarah L. Kerns
Medical College of Wisconsin, Milwaukee, WI 53226, USA

Dr. William A. Hall
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Deadline for manuscript submissions:
closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue on Genomics-Guided Radiotherapy in Cancer. Advances in human genomics have enabled personalized medicine in oncology, guiding screening, prognosis, and treatment selection to improve cancer outcomes. In Radiation Oncology, recent advances in uncovering the genomic basis of tumor and tissue response to radiation could be used to guide patient selection, optimize radiotherapy plans, inform targeted use of increasingly conformal radiation modalities, and point to novel radiobiologic mechanisms for development of new sensitizing or mitigating agents.

This Special Issue aim to highlight the current state of the science in malignant and normal tissue radiation response with a focus on future prospects for improving personalization of treatment planning and development of mechanistically targeted tumor radiosensitizers and normal tissue radioprotectors. Original research articles and reviews are welcome.

We look forward to receiving your contributions.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us